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Aims T-lymphocytes plays an important role in the pathophysiology of acute coronary syndromes. T-cell activation
in vitro by pro-inflammatory cytokines may lead to functional tissue factor (TF) expression, indicating a possible
contribution of immunity to thrombosis. Oxidized low-density lipoproteins (oxLDLs) are found abundantly in ath-
erosclerotic plaques. We aimed at evaluating the effects of oxLDLs on TF expression in T cells and the role of the




CD3þ cells were isolated from healthy volunteers. Gene, protein, and surface expression of TF, as well as of
LOX-1, were assessed at different time-points after oxLDL stimulation. To determine whether oxLDL-induced TF
was LOX-1 dependent, T cells were pre-incubated with an LOX-1 inhibiting peptide (L-RBP) or with an anti-LOX-
1 blocking antibody. To exclude that TF expression was mediated by reactive oxygen species (ROS) generation,
oxLDL-stimulated T cells were pre-incubated with superoxide dismutase þ catalase or with 4-Hydroxy-2,2,6,6-tet-
ramethylpiperidine-1-oxyl (Tempol), an intracellular free radical scavenger. Finally, to determine if the observed
findings in vitro may have a biological relevance, the presence of CD3þ/TFþ/LOX-1þ cells was evaluated by immu-
nofluorescence in human carotid atherosclerotic lesions. oxLDLs induced functionally active TF expression in
T cells in a dose- and time-dependent manner, independently on ROS generation. No effect was observed in native
LDL-treated T cells. LOX-1 expression was also induced by oxLDLs in a time- and dose-dependent manner.
Pre-incubation with L-RBP or anti-LOX-1 antibody almost completely inhibited oxLDL-mediated TF expression.
Interestingly, human carotid plaques showed significant infiltration of CD3þ cells (mainly CD8þ cells), some of
which were positive for both TF and LOX-1.
....................................................................................................................................................................................................
Conclusion oxLDLs induce functional TF expression in T-lymphocytes in vitro via interaction of oxLDLs with LOX-1. Human
carotid atherosclerotic plaques contain CD3þ/CD8þcells that express both TF and LOX-1, indicating that also in
patients these mechanisms may play an important role.
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Atherosclerosis is a lipoprotein-driven, inflammatory disease character-
ized by deposition of low-density lipoproteins (LDLs) and other
blood-borne materials within the arterial wall of almost all vascular dis-
tricts.1 Furthermore, it has been convincingly demonstrated that within
coronary vessels, infiltration of immune-competent cells, such as
macrophages and T-lymphocytes, plays an important role not only in the
progression of atherosclerosis but also in plaque destabilization, leading
to the clinical scenario of acute coronary syndromes (ACS).2
We have previously reported that coronary plaques obtained from
ACS patients show a selective, oligoclonal expansion of T cells, indicating
a specific, antigen-driven recruitment of T-lymphocytes within the
unstable lesions.3 To date, however, the antigen(s) responsible for this
recruitment still remain elusive, although it has been postulated that
oxidized-LDLs (oxLDLs) might represent a good candidate.4–6 Quite re-
cently indeed, Liu et al.7 have demonstrated that oxLDLs induce activa-
tion of T-lymphocytes in presence of dendritic cells, further supporting
the notion that oxLDLs may act, under certain conditions, as a non-self-
antigen. However, within the atherosclerotic plaque microenvironment,
several stimuli may act simultaneously on the resident cells, including
T-lymphocytes, thus contributing to their activation via mechanisms
different from the ‘classical’ interaction of the antigen with the T-cell
receptor.8 For example, as reported by our group, stimulation of T-lym-
phocytes with selected pro-inflammatory cytokines in vitro induce a
pro-thrombotic phenotype via expression of functional tissue factor
(TF), the main initiator of the coagulation cascade.9 Interestingly, this
phenomenon seems to occur also in vivo in ACS patients.8
Internalization and degradation of oxLDLs is mediated by a lectin-like
52-kD receptor, namely lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1).10 Since its discovery, several studies have described
the role of LOX-1 in atherosclerosis and cardiovascular disease.11
According to the available data, we hypothesized that oxLDLs might
induce TF expression in T-lymphocytes via a mechanism different
from the immunological activation of T cells, i.e. antigen/T-cell receptor
interaction. In particular, the role of LOX-1, also expressed in
T-lymphocytes,12 was investigated. We report here that oxLDLs, but
not native LDLs, induce functionally active TF expression in T cells via in-
teraction with LOX-1 and that human carotid plaques contain CD3þ/
TFþ/LOX-1þ cells, providing evidence for a novel mechanism of T-cell
activation within atherosclerotic plaques. The potential implications of
these findings in human disease are also discussed.
2. Methods
Expanded methods are provided in Supplementary material online.
2.1 Experimental protocol
LDLs (density 1.019–1.063 g/mL) and oxLDLs were prepared as previ-
ously described.13 T-lymphocytes were isolated from daily fresh human
buffy coats of 15 healthy volunteers as previously described.9 A written
informed consent was obtained from each subject. The protocol was
approved by the local ethical committee and conform the principles
outlined in the declaration of Helsinki.

































































































In preliminary experiments, a dose–response curve to oxLDLs was
performed (25, 50, and 100mg/mL). oxLDLs at 25mg/mL induced a slight
but non-significant increase in TF expression, while a significant increase
in TF expression was observed at 50 and 100mg/mL, although the latter
was associated with some cytotoxicity. Based on these preliminary
experiments, T cells (1 106/mL) were incubated with either oxLDLs
(50 and 100mg/mL) or native, non-oxidized LDLs as internal control. To
determine whether oxLDLs induce expression of TF in T cells, TF
mRNA analysis was performed at different time-points (4, 8, 12, 18, 24,
48, and 72 h) following stimulation. TF protein levels by western blot, as
well as flow cytometry analysis and TF functional assay in intact cells
were performed at 72 h. To determine whether oxLDL-induced
TF expression in T-lymphocytes was mediated by expression and activa-
tion of LOX-1, further experiments were performed. First, LOX-1 ex-
pression was evaluated following stimulation with oxLDLs, as above
described, both at gene and protein level. In a second set of experiments,
T cells were pre-incubated for 30 min with an LDL receptor blocking
peptide (L-RBP, Cayman Chemical, Ann Arbor, MI) (5 and 10mg/mL final
concentration) or a neutralizing monoclonal antibody against human
LOX-1 (TS92, 10mg/mL; characteristics of the antibody were described
in previous reports).14,15 Then, T-lymphocytes were incubated with
oxLDLs (50mg/mL). TF gene, protein, and activity levels were evaluated
as above described.
To determine which intracellular signalling pathways are activated by
LOX-1/oxLDL interaction, the contributions of p47 (one of the major
constituent of NADPH oxidase [NOX]), as well as of NF-jB (by west-
ern blot and translocation assay as previously described16), were investi-
gated. The effects of NOX inhibition by diphenyleneiodonium (DPI,
obtained from Sigma-Aldrich, St. Louis, MO, D2926) were also evalu-
ated. T cells were pre-treated with DPI at final concentration of 500mM
as already described17 for 1 h and subsequently stimulated with oxLDL
(50mg/mL) for 24 and 48 h for mRNA analysis.
Furthermore, to determine whether the observed effects on TF
expression in oxLDLs stimulated T cells were specific of LOX-1/oxLDL
interaction or caused by a generic lipid peroxidation/reactive oxygen
species (ROS) generation phenomenon, additional experiments were
performed: (i) T cells were stimulated with H2O2 (50 and 100lM)
18 and
TF expression was evaluated at gene and protein levels. LOX-1 gene
expression was also investigated; (ii) T cells were pre-incubated
with superoxide dismutase (SOD, 500 U/mL)16,19 and catalase
(300 U/mL)20,21 for 30 min and then stimulated with oxLDLs 50lg/mL;
(iii) T cells were pre-incubated for 1 h with 4-Hydroxy-2,2,6,6-tetrame-
thylpiperidine-1-oxyl (Tempol, 10lM), a membrane-permeable ami-
noxyl-type free radical scavenger, with unique antioxidant
properties.22,23 Cells were then stimulated with oxLDLs and expression
of TF was evaluated as above described. The amount of lipid peroxida-
tion was determined by measuring lipid peroxidation products both after
oxLDLs and H2O2 stimulation.
For each peripheral blood mononuclear cell (PBMC) preparation,
three independent experiments for all of the conditions above described
were performed.
2.2 Real-time PCR
Total RNA was isolated using Trizol Reagent, according to the manufac-
turer’s protocol. Amplification of LOX-1 from cDNA was performed us-
ing the following primers (Sigma-Aldrich): fw: 50-TGGGAAAAG
AGCCAAGAGAA-30, rev: 50-TAAGTGGGGCATCAAAGGA-30. TF
and housekeeping gene TBP (TATA Box protein) primers were previ-
ously described.9
2.3 Collection of cell lysates and protein
expression
Protein analysis was performed on T-cell lysates at 72 h following stimu-
lation with oxLDLs and at 4, 8, 12, 18, and 24 h after stimulation with
H2O2. For molecular pathways analysis, cell lysates were collected 8, 16,
and 24 h following stimulation with oxLDLs (50mg/mL) with or without
L-RBP (10mg/mL) or a blocking monoclonal antibody against human
LOX-1 (TS92, 10mg/mL). Blots were incubated overnight at 4C with
anti-TF antibody (Affinity Biologicals) diluted 1:1000 in TBS with 0.1%
Tween-20 and 2.5% non-fat dry milk. For molecular pathways analysis,
anti-NF-jB (Biorbyt, Cambridge, UK), anti-IjB (Thermo Fisher,
Waltham, MA), and anti-p47 phosphorylated antibody (Thermo Fisher)
were used.
2.3 Flow cytometry analysis
Ten million T cells, isolated as above described, were plated in X-Vivo
medium and treated with oxLDL (50mg/mL) for 72 h. Surface TF expres-
sion as well as CD8/CD4 subpopulations characterization was
performed.
2.4 TF activity in intact T cells
TF procoagulant activity was measured as previously described.9
2.5 Quantification of lipid peroxidation
products
The extent of lipid peroxidation in cell lysates was determined by mea-
suring malonyldialdehyde (MDA) levels, a secondary lipid peroxidation
product. The thiobarbituric acid method (TBARS assay kit, Cayman
Chemical) was used and results were expressed as micromolar of MDA
generated.13
2.6 Confocal microscopy of T cells
To evaluate surface expression and distribution of LOX-1 on T-cell
membrane, we performed confocal microscopy experiments. Briefly,
T-lymphocytes (3 106) were incubated with oxLDLs (50 lg/mL) for
72 h. Cells were then incubated with primary antibody (Anti-LOX 1,
purchased from Abcam, Cambridge, UK) for 1 h at RT, extensively
washed in phosphate buffer saline (PBS) and incubated with secondary
antibody (Alexafluor 546 goat anti mouse) for 1 h at RT. Cells were ex-
tensively washed in PBS, spotted on microscope slides, and analysed.
2.7 Immunohistochemistry of human
carotid atherosclerotic lesions
To determine whether T-lymphocytes co-localize with TF in vivo, immu-
nohistochemistry staining was performed using 4mm thick formalin-
fixed, paraffin-embedded (FFPE) tissue sections of atherosclerotic pla-
ques. Serial adjacent sections were treated as previously described.9,24
2.8 Immunofluorescence of human carotid
atherosclerotic lesions
Immunofluorescence was performed using 4 lm thick FFPE tissue sec-
tions of carotid plaques. Slides were treated as previously described.25
To evaluate the CD3 subset population co-expressing TF/LOX-1, immu-
nofluorescence (IF) was carried out by mean of Opal Multiplex IF
Assay26 (Perkin Elmer, Waltham, MA, USA) (gift of Prof. G. Matarese,
University ‘Federico II’, Naples, Italy) as suggested by the manufacturer
using 4mm thick FFPE tissue sections from atheroma.





































Results are expressed as mean ± SE. All data from in vitro experiments
were evaluated by D’Agostino–Pearson test for normal distribution.
One-way ANOVA followed by the Tukey test was used for multiple
comparisons. All analyses were performed using the GraphPad Prism
6.00 for Windows software (GraphPad Software, San Diego California,
USA).
3. Results
3.1 oxLDLs induce TF gene and protein
expression in T-lymphocytes
Incubation of T-lymphocytes with oxLDLs, but not with native LDLs,
induced TF gene expression in a dose- and time-dependent manner
(Figure 1A and inset), without affecting cell viability up to 50mg/mL (data
not shown). TF mRNA levels remained stable at baseline values
up to 18 h, increased up to about 25-fold the control values at 48 h of
incubation with oxLDLs 50mg/mL, and significantly decreased at 72 h
(Figure 1A). Taking into account the time-course of TF mRNA, protein
levels were investigated by western blot up to 72 h following oxLDL
stimulation. No detectable bands were observed at earlier time point
(18 and 24 h, while a faint band was present at 48 h, data not shown). TF
protein levels significantly increased at 72 h following exposure to
oxLDLs (Figure 1B). No significant effect was observed in T cells exposed
to native LDLs.
It has been previously demonstrated that oxLDLs result in a significant
peroxidation of cellular lipid membranes.27,28 Thus, to determine if
the observed effects of oxLDLs on TF expression in T cells were non-
specifically related to an increase in lipid peroxidation and/or ROS gener-
ation, T-lymphocytes were stimulated with H2O2 (50 and 100 lM).
H2O2 at both concentrations determined an increase in TF expression
both at gene and protein levels (Figure 1C and D). LOX-1 was also in-
duced in a dose- and time-dependent manner (Supplementary material
online, Figure S1). However, H2O2 stimulation of T cells resulted in a
much lower TF expression, as compared to oxLDLs. Most importantly,
induction of TF by H2O2 was much earlier with respect to oxLDLs, as
TF gene was already significantly induced at 4 h of stimulation. This time-
lag in TF expression between oxLDLs and H2O2 suggests that the effects
Figure 1 Effects of oxLDLs and H2O2 on TF expression by T-lymphocytes in vitro. CD3
þ lymphocytes were isolated from freshly prepared buffy coats
and stimulated with either native LDLs, oxLDLs, or H2O2. (A) oxLDLs induced a time- and dose-dependent increase in TF gene levels, as TF gene expression
increased significantly at 24 h, peaked at 48 h, and decreased significantly at 72 h following incubation with oxLDLs. Each column represents the mean ± SE of
15 experiments in triplicate (#P < 0.01, *P < 0.001 vs. Control; one-way ANOVA with Tukey’s post hoc test). Graph in the inset shows the dose-dependent
effects of oxLDLs (50 and 100mg/mL) at 48 h. (B) Changes in TF protein levels (measured by western blot analysis on cell lysates) paralleled those observed
for TF gene. TF protein significantly increased at 72 h in oxLDL-treated cells in a dose-dependent manner, while only a slight effect was observed in LDL-
stimulated cells. Each column represents the mean ± SE of 15 experiments in triplicate (*P < 0.001 vs. Control; one-way ANOVA with Tukey’s post hoc test).
(C) Incubation of T-lymphocytes with H2O2 induced a slight expression of TF gene in a dose- and time-dependent manner. However, the time-course of TF
expression was much earlier as compared to oxLDL-treated cells: TF gene levels reached the highest value at 8 h with a five-fold increase as compared to
unstimulated cells. Each column represents the mean± SE of 15 experiments in triplicate (#P < 0.01, *P < 0.001 vs. Control; one-way ANOVA with Tukey’s
post hoc test). (D) Changes in TF protein levels (measured by western blot analysis on cell lysates) paralleled those observed for TF gene. TF protein signifi-
cantly increased at 8 h in H2O2-treated cells in a dose-dependent manner. Each column represents the mean± SE of 15 experiments in triplicate (
#P < 0.01,
*P < 0.001 vs. Control; one-way ANOVA with Tukey’s post hoc test).
















































of oxLDLs were not related to an increase in lipid peroxidation but
rather mediated via activation of some other intracellular pathways.
Furthermore, pre-incubation with SOD and catalase did not significantly
affect oxLDL-induced TF expression, both at gene and protein levels
(Figure 2A and B), indicating that ROS generation does not significantly
contribute to TF induction by oxLDLs. To strengthen these findings, we
have also evaluated the effect of Tempol, an antioxidant that permeates
biological membranes, on oxLDL-treated T cells. Pre-incubation with
Tempol, similarly to SOD and Catalase, did not significantly affect
oxLDL-induced TF expression (Figure 2C).
3.2 TF induced in T-lymphocytes by oxLDLs
is translocated to the plasma membrane
and is functionally active
Fluorescence-activated cell sorting (FACS) analysis showed that oxLDL-
induced TF was translocated to the cell membrane of T cells as
compared to LDL-stimulated or control cells (Supplementary material
online, Figure S2). Of the overall CD3þ T-lymphocyte population,
61.1± 2.9% were CD4þ cells, while 33.6 ± 2.4% were CD8þ cells. Both
unstimulated subtypes did not significantly express TF on their mem-
brane, while following stimulation with oxLDLs, 7.3 ± 2.1% of CD4þ and
4.9 ± 1.5% of CD8þ were also TFþ (Figure 3A). Most importantly,
surface-expressed TF was also functional as shown in the activity assay
experiments reporting a significant increase in FXa generation from in-
tact T-lymphocytes (Figure 3B).
3.3 oxLDLs induce TF in T-lymphocytes
via expression of LOX-1 and activation of
NF-jB pathway: role of NADPH oxidase
The time-lag of TF expression in oxLDL-stimulated T cells as compared
to H2O2-stimulated cells suggested that the effects of oxLDLs were me-
diated by activation of a different intracellular pathway. Thus, we investi-
gated whether oxLDL-induced TF expression was mediated by
expression of LOX-1, the scavenger receptor of oxLDLs. Incubation of
T cells with oxLDLs, but not with LDLs, induced expression of LOX-1 in
a dose- and time-dependent manner (Figure 4A and inset). Gene levels
remained stable at baseline values up to 12 h. At 18 h, a two-fold increase
in LOX-1 gene levels was observed when T cells were incubated with
oxLDLs (50mg/mL), peaking up to six-fold the control values at 48 h
(Figure 4A). Interestingly, confocal microscopy analysis revealed that
unstimulated T cells express almost undetectable levels of LOX-1 on
their surface (Figure 4B); in contrast, exposure to oxLDLs (50mg/mL) for
72 h highly increased LOX-1 expression on T-cell surface (Figure 4B).
To verify whether TF expression in oxLDL-treated T-lymphocytes
was related to LOX-1 activation, we pre-treated T cells with a low-
density lipoprotein receptor blocking peptide (L-RBP) and anti-LOX-1
blocking antibody. Pre-incubation with L-RBP, as well as with the anti-
LOX-1 antibody resulted in a significant suppression of oxLDL-induced
TF expression both at gene and protein levels (Figure 5A, B, D, and E). TF
procoagulant activity was also significantly reduced by both, L-RBP and
TS92 (Figure 5C). Of note is the finding that L-RBP did not affect LOX-1
gene expression, as shown in Figure 5D.
Figure 2 Effects of antioxidants (superoxide dismutase, catalase, and Tempol) on TF expression induced by oxLDLs. T-lymphocytes were pre-incubated
with superoxide dismutase (SOD, 500 U/mL) and catalase (300 U/mL) or Tempol (10 lM) before stimulation with oxLDLs. SOD and catalase or Tempol
did not significantly affect TF expression at gene (A and C) and protein levels (B). Each column represents the mean ± SE of 15 experiments in triplicate.
Statistical analysis made by one-way ANOVA with Tukey’s post hoc test. NS, not significant.























































Binding of oxLDLs to LOX-1 resulted in activation of NADPH oxi-
dase (NOX) on the cell surface, as suggested by the increase in intracel-
lular p47 levels, which in turn resulted in increased cytosolic levels of
NF-jB and reduced levels of IjB (Figure 6A). The NOX is a multicompo-
nent enzyme with up to six subunits, including p47-phox29; NOX activa-
tion on the cell surface usually results in intracellular ROS formation,
ultimately leading to the redox-sensitive NF-jB signalling pathway.30,31
Interestingly, pre-incubation with the L-RBP significantly reduced p47
phosphorylation and NF-jB activation, while it increased IjB levels
(Figure 6A). NF-jB translocation is also reduced by anti-LOX-1 antibody
(Figure 6B). Furthermore, DPI, a potent inhibitor of NADH/NADPH
oxidase,17 resulted in a significant inhibition of TF gene expression
(Figure 6C).
To evaluate if the observed effects oxLDLs on TF expression were re-
lated at least in part to the lipid peroxidation induced by oxLDLs, we
have measured lipid peroxidation products, expressed as concentration
of MDA levels following stimulation with oxLDLs or H2O2. MDA levels
were significantly higher in H2O2-treated cells at both concentrations, as
compared to oxLDL-treated cells (Supplementary material online, Figure
S3A). However, while incubation of T cells with H2O2 induced expres-
sion of LOX-1 mRNA in a dose- and time-dependent manner to a higher
extent as compared to oxLDLs (Supplementary material online, Figure
S3B), H2O2 induced only a slight increase in TF expression, again as
compared to oxLDL-stimulated cells (Supplementary material online,
Figure S3C).
3.4 T-lymphocytes in human carotid
atherosclerotic plaques express both
LOX-1 and TF on their surface
Immunohistochemistry staining of atherosclerotic lesions collected
from patients undergoing thromboendarterectomy (TEA) resulted cell
enriched, as evidenced by haematoxylin and eosin staining (Figure 7,
Panel 1A). Some of these cells were T-lymphocytes, as they were
positive for CD3 antigen (Figure 7, Panel 1B), some of which were also
positive for TF antigen (Figure 7, Panel 1C).
3.5 Immunofluorescence on human carotid
atherosclerotic lesion
We asked if T-lymphocytes present in atherosclerotic lesions expressing
TF were also able to express LOX-1 protein. We performed immuno-
fluorescent staining of human carotid atherosclerotic lesions with rabbit
monoclonal anti-CD3 and mouse monoclonal anti-LOX-1 antibodies,
or on consecutive serial section, rabbit polyclonal anti-TF. Results are
shown in Supplementary material online, Figure S4. T-lymphocytes
CD3þ expressed LOX-1 and TF. Successively we asked which class of
T-lymphocytes was represented in human carotid atherosclerotic
lesions. We performed immunofluorescence and confocal microscopy
on FFPE 4 lm thick sections from human carotid atherosclerotic lesions
using the Opal kit (see Section 2) with antibodies anti CD4, TF, LOX-1,
and on a consecutive serial section with antibodies anti CD8, TF, and
LOX-1. As shown in Figure 7, Panel 2, in carotid atherosclerotic lesions,
lymphocytes CD8þ that were also TFþ and LOX-1þ were present.
Antibody anti CD4 gave no staining.
4. Discussion
In the present study, we report for the first time that oxLDLs but not
native LDLs induce a pro-thrombotic phenotype in T-lymphocytes by
inducing TF expression via activation of LOX-1 receptor. Of note is
the observation that TF was translocated to the cell membrane and
was functionally active. This observation is in line with and extends our
Figure 3 TF surface expression in oxLDL-treated T-lymphocytes. (A) FACS analysis was performed on live cells (red colour in 7-AAD-A box) and
showed that oxLDL-induced TF was translocated to the cell membrane of T cells. Because of oxLDL toxicity some cells died (green colour), thus reducing
the total cell population. Of the overall CD3þ T-lymphocyte population, 61.1± 2.9% were CD4þ cells, while 33.6± 2.4% were CD8þ cells. Both unstimu-
lated subtypes did not significantly express TF on their membrane, while following stimulation with oxLDLs, 7.3 ± 2.1% of CD4þ and 4.9 ± 1.5% of CD8þ
were also TFþ (Figure 3A). (B) TF procoagulant activity in intact T cells was measured by a modified chromogenic TF assay (see text for details). oxLDL stim-
ulation resulted in a significant increase in FXa generation, as compared to unstimulated cells or cells treated with native LDLs, indicating that TF was translo-
cated to the cell membrane in an active form. Activity of 6 pM recombinant re-lipidated TF (rTF) is reported as an internal control. Each column represents
the mean ± SE of 15 experiments in triplicate (*P < 0.001 vs. Control; one-way ANOVA with Tukey’s post hoc test).









































..previous findings that selected pro-inflammatory cytokines may induce
active TF expression in isolated T cells (cells membrane and bearing
microparticles9) in vitro and in patients with ACS.8
Another interesting finding of the present study is that the effects
on T cells were not related to an increase in oxidative stress via lipid per-
oxidation/ROS generation but instead were mediated by the induction/
activation of LOX-1. Indeed, experiments conducted in presence of
L-RBP, an inhibitor of LDL binding to its receptor, or a blocking mono-
clonal antibody against human LOX-1, almost completely suppressed
oxLDL-induced TF expression.
We have also analysed the expression of TF in T-cell resident within
human atherosclerotic lesions obtained from patients undergoing TEA.
Immunohistochemistry analysis showed that these lesions were enriched
in CD3þ/CD8þcells, most of which were also TFþ and LOX-1þ. In addi-
tion, immunofluorescence analysis of the same plaques revealed the
presence of T cells expressing both TF and LOX-1, indicating the poten-
tial clinical relevance of the findings observed in vitro.
Taken together, the data of the present study demonstrate, for
the first time, that T-lymphocytes exposed to oxLDLs acquire a pro-
thrombotic phenotype by expressing functional TF on their membrane,
as already reported for monocytes,32 independently on the potential role
of oxLDLs as a non-self-antigen, namely via activation of LOX-1, and that
within atherosclerotic lesions, these cells might directly contribute to
the onsite thrombotic process in vivo, linking atherosclerosis, immunity
and thrombosis in a single multi-step process.
It is widely recognized that atherosclerosis is an inflammatory disease,
where immunocompetent cells producing pro-inflammatory cytokines
are abundant in atherosclerotic lesions.33 In addition, important compo-
nents of the atherosclerotic plaque include dead cells, debris, and modi-
fied forms of lipids, particularly oxLDLs.34 It has been convincingly
demonstrated that T cells with pro-inflammatory properties (i.e. Th1
subsets) play a key role not only in initiating the development of the ath-
erosclerotic plaque, but also in promoting its complication (rupture, fis-
suration, etc.), leading to the clinical occurrence of ACS. For example,
several studies have demonstrated that complicated plaques show a
higher content of inflammatory cells, often located near the site of rup-
ture, thus suggesting an active role in plaque rupture (for review, see ref.
34). In a study from our group employing coronary plaque specimens
obtained during directional coronary atherectomy from living patients
with ACS we have investigated the T-cell repertoire, demonstrating a
specific, immune-driven activation of T cells within unstable plaques.3 In
particular, we have shown that unstable plaques contain a much greater
T-cell infiltration than stable plaques and that the T-cell receptor (TCR)
repertoire within the unstable plaques was highly skewed in all patients
with ACS, as compared to patients with stable angina, indicating a specific
antigen-driven T-cell recruitment within the culprit lesions of patients
Figure 4 Effects of oxLDLs on LOX-1 expression by T-lymphocytes in vitro. CD3þ lymphocytes were isolated from freshly prepared buffy coats and stim-
ulated with either native LDLs or oxLDLs. (A) oxLDLs induced a time- and dose-dependent increase in LOX-1 gene levels, as its expression increased signifi-
cantly at 18, 24, and 48 h following incubation with oxLDLs. Each column represents the mean± SE of 15 experiments in triplicate (#P < 0.01, *P < 0.001 vs.
Control; one-way ANOVA with Tukey’s post hoc test). Graph in the inset shows the dose-dependent effects of oxLDLs (50 and 100mg/mL) at 24 and 48 h.
(B) For confocal microscopy experiments, T-lymphocytes (3 106) were incubated with oxLDLs (50 lg/mL) for 72 h. Cells were then incubated with 0.5%
Cell Marker Deep Red, fixed in 4% para-formaldehyde and stained with a primary antibody anti-human LOX-1 and incubated with a secondary antibody.
Experiments were carried out on an inverted and motorized microscope. Fluorescence emission was revealed by main dichroic beam splitter and variable
secondary dichroic beam splitter. Triple staining fluorescence images were acquired separately in the blue, red, and infra-red channel. Unstimulated cells
expressed very low (almost undetectable) levels of LOX-1 on cell surface (red colour). Exposure to oxLDLs (50mg/mL) for 72 h highly increases LOX-1 ex-
pression on T-cell surface.


































.with ACS.3 However, the search for of the putative antigen(s) responsi-
ble for the local activation of the T cells still remains elusive.
According to the leading hypothesis, modified forms of LDLs,
including oxLDLs may play an important role in the occurrence of plaque
complication by being recognized as non-self-antigens by T-lymphocytes.
Previous studies have indeed suggested that oxLDLs can function as T-
cell antigens in the context of atherogenesis;35,36 interestingly, Liu et al.7
have recently demonstrated that enzymatically modified forms of LDLs,
but not native LDLs, promote dendritic cell maturation and T-cell
activation, suggesting an involvement of the TCR. Whether oxLDLs may
induce TF in dendritic cells via activation of LOX-1 is not known at the
moment; it should be pointed out, however, that in the present study we
provide evidence of the interplay between T-lymphocytes and oxLDLs
in a way different from the ‘classical’ TCR-mediated activation of
lymphocytes. In fact, we have shown that oxLDLs may activate T cells via
induction of the scavenger receptor, LOX-1. Binding of LOX-1
to oxLDLs then induced expression of functional TF on the T-cell
membrane. Confocal microscopy experiments confirmed that LOX-1 is
almost undetectable in unstimulated T cells, while it is highly expressed
on T-cell membrane following exposure to oxLDLs.
Another potential mechanism by which oxLDLs may activate T-lym-
phocytes is represented by an increase in oxidative stress. For example,
it is well established that oxLDLs increase intracellular levels of ROS and
lipid peroxidation end-products.28 To verify if TF expression was related
to an oxLDL-induced oxidative stress, we have conducted two different
sets of experiments: first, we have quantified lipid peroxidation in T cells
stimulated with oxLDLs or hydrogen peroxide. Secondly, we have
measured TF and LOX-1 expression in H2O2-treated cells and have
compared it with that obtained after oxLDL stimulation. Although H2O2
induced significantly higher levels of lipid peroxidation than oxLDLs, the
effects on TF expression were of a significantly lesser order of magni-
tude. Interestingly, H2O2 induced high levels of LOX-1 gene as early
as 4 h in a time- and dose-dependent manner. We may speculate that
peroxidation by H2O2 induces early expression of LOX-1, that is
used by oxLDLs for binding and amplification of LOX-1 expression in
line with other observation in different cells type.37,38 More important,
Figure 5 Effects of LOX-1 inhibition on TF and LOX-1 expression by T-lymphocytes stimulated with oxLDLs. T cells were pre-incubated with a low-
density lipoprotein receptor blocking peptide (L-RBP) or anti-LOX-1 blocking antibody and then stimulated with oxLDLs. (A and B) L-RBP resulted in a
dose-dependent suppression of TF expression at gene and protein levels (*P < 0.001, #P < 0.01 vs. Control; one-way ANOVA with Tukey’s post hoc test).
(C) TF procoagulant activity is significantly affected by L-RBP and anti-LOX-1 blocking antibody pre-treatment (*P < 0.001, #P < 0.01 vs. Control; one-way
ANOVA with Tukey’s post hoc test). (D and E) Anti-LOX-1 blocking antibody resulted in a significant suppression of TF expression at gene and protein levels
(*P < 0.001, #P < 0.01 vs. Control; one-way ANOVA with Tukey’s post hoc test).(F) In contrast, L-RBP had no effect on LOX-1 gene expression (D).
Each column represents the mean± SE of 15 experiments in triplicate.





































in oxLDL-treated cells, pre-incubation with SOD and catalase did not af-
fect significantly TF expression. In addition, pre-treatment with Tempol,
an intracellular antioxidant, did not significantly affect oxLDL-induced TF
expression. These findings, together with the observation that in T cells
stimulated with oxLDLs in presence of L-RBP, an inhibitor of LDL bind-
ing to its receptor, or a blocking anti-LOX-1 antibody, TF expression
was almost completely abolished clearly indicate that the effects of
oxLDLs on T cells are largely mediated via interaction with LOX-1.
Finally, one additional observation further supports this conclusion:
binding of oxLDLs to LOX-1 activates NADPH oxidase on the cell
membrane that results in rapid formation of intracellular ROS,29 which
in turn activate the redox-sensitive NF-jB signalling pathway, generating
different intracellular responses.30,31
The NADPH oxidase (NOX) is a multicomponent enzyme made up
of six subunits: a Rho guanosine triphosphatase (GTPase) and five ‘phox’
units, one of which is p47.39 NOX is known to be one of the major sour-
ces of intracellular ROS. Once activated, the G proteins Rac1 or Rac2
and the phosphorylated cytoplasmic p47phox subunit initiate migration
of the cytosolic elements to the plasma membrane, to form a functional
complex that generates ROS.40 The p47phox acts as a regulatory subu-
nit of NOX to initiate assembly of active oxidase, which is important for
NOX activation.39 It has been reported that inhibition of p47phox abro-
gated NOX function and diminished ROS production in ovarian
and prostate cancer cells.41 Depending on the level of ROS, different
redox-sensitive transcription factors are activated and co-ordinate dis-
tinct biological responses. An intermediate amount of ROS triggers
an inflammatory response through the activation of NF-jB and AP-1.
NF-jB was the first transcription factor shown to be redox-regulated.42
In the present study, oxLDLs/LOX-1 interaction induced NAPDH ox-
idase activation as shown by the increased levels of p47 that in turn
resulted in increased cytosolic levels of NF-jB and reduced levels of IjB.
Conversely, pre-incubation with L-RBP significantly blunted the increase
in p47 and NF-jB, while it increased IjB. In line with these results is the
observation that the use of DPI, a potent NAPDH oxidase inhibitor, sig-
nificantly reduced oxLDL-induced TF expression.
In conclusion, the present study shows for the first time that T cells
may acquire a pro-thrombotic phenotype via expression of functional
TF in response to oxLDLs and that this phenomenon is largely mediated
Figure 6 Intracellular molecular pathways activated by oxLDL stimulation of T-lymphocytes. T-lymphocytes were stimulated with oxLDLs for 8, 16, and
24 h. Cell lysates were used to measure cytosolic NADPH and NF-jB activation. (A) Western blots analyses. oxLDLs/LOX-1 interaction induced NAPDH
oxidase activation, as shown by the increased levels of p47 phox (one of the intracellular subunit of the NADPH system) that in turn resulted in increased
cytosolic levels of NF-jB and reduced levels of IjB. Conversely, pre-incubation with L-RBP, reduced significantly p47-phox and NF-jB and increased IjB.
(B) NF-jB translocation to the nucleus is significantly reduced by L-RBP and anti-LOX-1 blocking antibody pre-incubation (*P < 0.01 vs. CTRL, #P < 0.01 vs.
oxLDL; one-way ANOVA with Tukey’s post hoc test). (C) T cells pre-incubated with DPI (500lM) resulted in a significant inhibition of TF gene expression
(*P < 0.01 vs. CTRL, #P < 0.01 vs. oxLDL; one-way ANOVA with Tukey’s post hoc test).






























..by activation of LOX-1. Taken together with previous studies3,9,43,44
data of the present study support the relevant contribution of T cells in
atherosclerosis and thrombosis. Considering the key role of LOX-1 in
this mechanism, future studies exploring the effects of its modulation in
the clinical scenario of acute cardiovascular events are warranted.
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Supplementary material is available at Cardiovascular Research online.
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Translational perspectives
Despite significant advancements have been made in antithrombotic therapy, current strategies still fail to prevent acute thrombotic coronary events
in a substantial number of patients, indicating that the complex mechanisms underlying the pathophysiology of ACS are not fully elucidated. The pre-
sent study demonstrates, for the first time, that T-lymphocytes may express functional TF in response to oxLDLs via mechanisms other than the ‘clas-
sical’ activation of the T-cell receptor, namely via interaction with LOX-1. Further studies aimed at interfering with LOX-1 in T-lymphocytes might
offer innovative and additional therapeutical approaches for ACS patients.
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